12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Endo Pharmaceutical Holdings Inc., Novartis sales and marketing update

In its 1Q12 earnings, Endo said it is now able to provide a "steady supply" of its crush-resistant formulation of Opana ER oxymorphone and Voltaren Gel...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >